Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme
Author:
Open Access
- 1 January 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 55 (1) , 212-225
Abstract
Despite intensive efforts, the development of novel drugs for the treatment of sepsis has proved to be extremely difficult. A large number of clinicaKeywords
This publication has 13 references indexed in Scilit:
- Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shockThe Lancet, 1998
- Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsisThe Lancet, 1997
- The Effects of Ibuprofen on the Physiology and Survival of Patients with SepsisNew England Journal of Medicine, 1997
- Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia.Journal of Experimental Medicine, 1996
- Statistical Considerations for the Design of the Optimal Clinical Trial1995
- Evaluation of the Adequacy of Source Control1995
- Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.Journal of Experimental Medicine, 1994
- Inhibition of Nitric Oxide Synthase in Experimental Gram-Negative SepsisThe Journal of Infectious Diseases, 1994
- A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndromeCritical Care Medicine, 1993
- Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.Journal of Experimental Medicine, 1990